In this conversation, Mazen Noureddin fields questions from Jörn Schattenberg, Louise Campbell and Roger Green around different application settings for the Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF). The group discusses pros and cons of different approaches and speculate on challenges such as cost effectiveness and ease of use.
In this conversation, Mazen Noureddin introduces his recent work around serum identification of at-risk MASH and the recent paper he co-authored on the subject. He describes the aims of the study as well as provides a cogent background for why this work came to be and maintains its relevance.
Surfing NASH returns to its regular program with a fresh episode and some fascinating and progressive ideas on non-invasive testing with Mazen Noureddin. For this feature, Mazen talks about his recent work in serum identification of at-risk MASH and the Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF). The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) respond with their thoughts and varying perspectives.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes. This segment features ideas around how health care systems can improve and important lessons learned from the COVID pandemic.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes. This segment introduces three important questions that the group aims to answer throughout the wider episode.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes.
What do liver nursing KOLs see as the largest, most important changes they can hope for 2-3 years from now?
As efficacious NASH drugs near the market, what steps can we take to ensure that patients receive treatment early enough in the course of therapy?
How does the misalignment of liver patients’ needs and nursing availability limit chances to intervene early in the course of Fatty Liver disease?
